Literature DB >> 18097557

Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.

D Carlisi1, B Vassallo, M Lauricella, S Emanuele, A D'Anneo, E Di Leonardo, P Di Fazio, R Vento, G Tesoriere.   

Abstract

This report shows that histone deacetylase inhibitors (HDACIs) induced apoptosis in human hepatoma HepG2 cells in a dose- and time-dependent manner. Trichostatin A (TSA), ITF2357 and suberoylanilide hydroxamic acid (SAHA), which were very effective agents, caused apoptotic effects after a lag phase of 12-16 h. In order to elucidate the mechanism of HDACIs action in HepG2 cells we have studied the effects of TSA, ITF2357 and SAHA on acetylation of p53 and histones H2A, H2B, H3 and H4. It was observed that HDACIs rapidly induced acetylation of these proteins, being the effects clearly visible already at 30 min of treatment at the same doses which caused apoptosis. Analysis of the immunocomplexes, obtained from nuclear extracts using an antibody against p53, revealed the presence of acetylated p53 together with acetylated forms of histones and histone acetyltransferases p300 and PCAF. Experiments performed using pifithrin-alpha, a reversible inhibitor of p53, showed a correlation between acetylation of p53 and induction of apoptosis. In addition treatment with siRNA against p53 indicated that p53 is involved in the acetylation of histones. In conclusion, this report suggests that complexes constituted by acetylated p53, acetylated histones and coactivators can play a central role in HDACI-induced apoptosis in HepG2 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097557     DOI: 10.3892/ijo.32.1.177

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  24 in total

Review 1.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 2.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin.

Authors:  Juhui Qiu; Guixue Wang; Jianjun Hu; Qin Peng; Yiming Zheng
Journal:  Mol Cell Biochem       Date:  2011-06-01       Impact factor: 3.396

4.  The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Authors:  Brian M Zeglis; NagaVaraKishore Pillarsetty; Vadim Divilov; Ronald A Blasberg; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

Review 5.  Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

Authors:  Stephen L Chan; Winnie Yeo
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

6.  Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Authors:  Chithra D Palani; James F Beck; Jürgen Sonnemann
Journal:  Invest New Drugs       Date:  2010-08-03       Impact factor: 3.850

7.  Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma.

Authors:  Bu-Dong Zhu; Xiao-Li Li; Yong Liu; Jing Chang; Yang Liu; Dong-Dong Zhang; Qiang Wang; Jun Ren; Chun-Ping Cui
Journal:  Clin Exp Metastasis       Date:  2010-08-04       Impact factor: 5.150

8.  Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.

Authors:  Bo Liao; Huifang Liang; Jin Chen; Qiumeng Liu; Bixiang Zhang; Xiaoping Chen
Journal:  Tumour Biol       Date:  2015-06-25

9.  Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.

Authors:  Johannes E A Wolff; Christof Kramm; Rolf-Dieter Kortmann; Torsten Pietsch; Stefan Rutkowski; Norbert Jorch; Astrid Gnekow; Pablo Hernáiz Driever
Journal:  J Neurooncol       Date:  2008-08-05       Impact factor: 4.130

Review 10.  Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives.

Authors:  Li Ma; Mei-Sze Chua; Ourania Andrisani; Samuel So
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.